HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss

Abstract excerpt

HER2-positive breast cancer (HER2+ BC) is an aggressive subtype with a poor prognosis. Although the antibody trastuzumab, which targets the HER2 growth factor receptor, has improved survival rates, patients often present with de novo resistance or acquire resistance after an initial response. Identifying new ways to target HER2 signaling will be critical for overcoming trastuzumab resistance. FAM83A is a novel...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HER2/EGFR in Cancer Research
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Peptidase Inhibition and Analysis